Overview: TandemAI, in collaboration with Oracle NetSuite and MeLin, launches a cloud ERP partnership to empower the entire drug R&D process with a digital platform, accelerating its global strategic expansion.
In today’s global market, which resembles a grand chessboard, companies seeking success must not only possess strong technological capabilities but also adopt strategic foresight for long-term development. Suzhou TandemAI Technology Co., Ltd. (hereinafter “TandemAI”) is a platform-based technology company dedicated to reshaping the drug molecule discovery process using advanced computational technologies. By combining a high-performance computing platform driven by quantum mechanics and artificial intelligence with scalable and efficient laboratories, TandemAI provides one-stop solutions to accelerate the discovery of drug molecules and reduce R&D costs.
Recently, TandemAI, together with Oracle NetSuite and partner Qingdao MeLin Information Technology Co., Ltd. (hereinafter “MeLin”), successfully held the Oracle NetSuite Cloud ERP Strategic Partnership Launch Ceremony. TandemAI CEO Mr. He Qi stated: “TandemAI chose to implement an ERP project at the early stage of the company not only to address the need for systems and tools to improve management efficiency but also to support a comprehensive digital strategy for the company’s rapid growth.”
TandemAI COO Dr. Tang Wei stated: “The full implementation and successful deployment of the ERP project within the company further empowers TandemAI to make data-driven decisions, supporting stable and efficient operations along our path of rapid growth. Choosing Oracle NetSuite also represents a convergence of two high-tech companies from different fields. We believe that, with the support of technology, the collaboration will spark even more innovation in the future.”
The year 2015 marked a new era for the development of China’s pharmaceutical industry, and in 2018, China saw a concentrated approval and launch of innovative drugs. The continued development of innovative drugs relies on technological breakthroughs and advancements, including enhanced computing power that enables the creation of more computational models and accelerates new drug R&D. However, due to cost and other constraints, many companies still cannot fully benefit from these technological advancements.
TandemAI aims to build a fully digital drug R&D process that covers all stages of drug development and connects upstream and downstream enterprises. This approach replaces traditional data exchange methods such as emails and PPTs, integrating fragmented data into a unified workflow.
Regarding TandemAI’s development vision, CEO Mr. He Qi said: “We have two missions: first, to increase accessibility to world-leading high-performance computing tools through a combined digital and wet-lab service model; second, to achieve full-process digitalization of R&D by integrating upstream and downstream capabilities, allowing more pharmaceutical companies to access the computing tools and laboratory services they need on the TandemAI platform.”
Global Coordination: Strong Collaboration to Build Integrated Management Processes
TandemAI’s business chain involves marketing management, R&D project management, supply chain management, and more. A unified ERP system is needed to connect R&D, finance, and operations across departments, improving overall operational efficiency.
At TandemAI, under the close collaboration of Oracle NetSuite and MeLin, the project quickly entered the implementation and deployment phase. As a strategic partner of Oracle NetSuite in the biopharmaceutical industry, MeLin worked with Oracle NetSuite to deliver a digital solution tailored for the pharmaceutical sector, leveraging extensive business insights and practical experience in supply chain and R&D project management.
With rich implementation experience ensuring a smooth deployment, TandemAI went from deployment to go-live in just three and a half months. After going live, the ERP system quickly transformed TandemAI’s previous business management and operational model, reshaping the company’s growth trajectory.
End-to-End Closed-Loop Management
TandemAI has achieved project-centric integrated business and financial management, effectively improving operational efficiency.
Optimized IT Costs
Oracle NetSuite, as a cloud-based ERP system and a pure SaaS platform, significantly reduces TandemAI’s investment in IT infrastructure and personnel costs, optimizing the previously fragmented operational model.
Unified Management, Security, Compliance, and Transformation of Excel-Based Financial Management
Oracle NetSuite provides a global tax and compliance framework, enabling TandemAI to establish a unified global management platform. This replaces the previous Excel-based financial management approach, efficiently integrating scattered data from finance, operations, and other modules. It not only generates actionable business insights but also meets tax and compliance requirements across different countries and regions.
TandemAI IT Head, Mr. Fan Weiyi, stated: “Phase one of the project went live, covering our core business processes from marketing management to R&D project management, supply chain management, project cost accounting, and financial analysis, helping us build a project-centric management framework.”
Global Vision, Full-Speed Advancement
“The cloud knows no borders. Oracle NetSuite’s powerful cloud DNA helped build a cloud-based global unified management platform, forming a project-centric management framework that lays a solid foundation for rapid business growth and global expansion.”
— He Qi, CEO of TandemAI Technology Co., Ltd.
Looking ahead, Oracle NetSuite will continue to support TandemAI’s global development. No matter how many branches TandemAI establishes worldwide, Oracle NetSuite will provide timely technical support, enabling rapid deployment. Employees across the globe can collaborate on a single platform, and through a one-stop platform solution, TandemAI can provide more comprehensive services for the drug R&D of other pharmaceutical companies.
